CDIO on Nasdaq
Cardio Diagnostics Holdings, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with NYMOX PHARMACEUTICAL CORP, Meridian Bioscience or Celldex Therapeutics, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-43737.5%Operating margin3
-43832.5%Net margin3
-57.5%Revenue growth, 20253
-93.2%Return on equity3
-$5.9MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development98¢$641.2K
- Interest2¢$14.8K
Out of $14.8K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $14.8K | $34.9K |
| Sales and marketing | $766.9K | $1.2M |
| Research and development | $641.2K | $228.0K |
| General and administrative | $5.0M | $6.9M |
| Amortization | $65.2K | $19.7K |
| Total operating expenses | $6.5M | $8.4M |
| Loss from operations | -$6.5M | -$8.4M |
| Interest income | $712 | $1.1K |
| Interest expense | -$14.8K | -$18.6K |
| Total other income (expenses) | -$14.1K | -$17.6K |
| Loss before provision for income taxes | -$6.5M | -$8.4M |
| Net loss | -$6.5M | -$8.4M |
| Net loss per common share, basic | -$3.71 | -$9.35 |
| Net loss per common share, diluted | -$3.71 | -$9.35 |
| Weighted average common shares outstanding, basic | 1.8M shares | 896.4K shares |
| Weighted average common shares outstanding, fully diluted | 1.8M shares | 896.4K shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-04-30 | 2024-12-31 |
|---|---|---|---|
| Cash | $5.1M | $7.8M | |
| Accounts receivable | $8.1K | $18.6K | |
| Prepaid expenses and other current assets | $801.9K | $944.7K | |
| Total current assets | $5.9M | $8.8M | |
| Property and equipment, net | $700.1K | $672.9K | |
| Right of use assets, net | $259.6K | $432.4K | |
| Intangible assets, net | $5.3K | ||
| Deposits | $12.8K | $12.8K | |
| Patent costs, net | $873.2K | $701.1K | |
| Total assets | $7.8M | $10.6M | |
| Accounts payable and accrued expenses | $97.4K | $87.7K | |
| Lease liability - current | $237.6K | $237.3K | |
| Finance agreement payable | $269.8K | $306.8K | |
| Total current liabilities | $604.8K | $631.7K | |
| Lease liability - long term | $188.2K | $425.8K | |
| Total liabilities | $793.1K | $1.1M | |
| Common stock, $.00001 par value; authorized - 300,000,000 shares; 1,826,051 and 1,531,468 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $18 | $15 | |
| Additional paid-in capital | $36.2M | $32.3M | |
| Accumulated deficit | -$29.2M | -$22.8M | |
| Total stockholders' equity | $7.0M | $9.6M | |
| Total liabilities and stockholders' equity | $7.8M | $10.6M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 100.0M shares | 100.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common Stock, Par or Stated Value Per Share | $0.00 | ||
| Common Stock, Shares Authorized | 300.0M shares | 300.0M shares | |
| Common Stock, Shares, Outstanding | 1.8M shares | 52.2M shares | 1.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$6.5M | -$8.4M |
| Depreciation | $160.1K | $113.8K |
| Amortization | $238.1K | $162.6K |
| Stock-based compensation expense | $110.2K | $2.6M |
| Accounts receivable | $10.5K | -$13.7K |
| Prepaid expenses and other current assets | $480.0K | $916.0K |
| Accounts payable and accrued expenses | $9.8K | -$155.6K |
| Lease liability | -$237.3K | -$223.9K |
| NET CASH USED IN OPERATING ACTIVITIES | -$5.7M | -$5.0M |
| Purchases of property and equipment | -$187.3K | -$214.8K |
| Patent costs incurred | -$232.0K | -$189.4K |
| NET CASH USED IN INVESTING ACTIVITIES | -$419.3K | -$404.2K |
| Proceeds from sale of common stock and warrants, net of issuance costs | $3.8M | $12.4M |
| Payments of finance agreement | -$374.2K | -$450.7K |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | $3.4M | $11.9M |
| NET (DECREASE) INCREASE IN CASH | -$2.7M | $6.5M |
| Interest | $14.8K | $18.6K |
| Financing agreement entered into for prepaid insurance | $337.2K | $383.5K |
Compare Cardio Diagnostics Holdings, Inc. with another company
Former names
- Mana Capital Acquisition Corp.Jul 20, 2021 to Oct 26, 20222
Recent filings
- Oct 2, 20264 PRIMARY DOCUMENT
- Oct 2, 20264 PRIMARY DOCUMENT
- Oct 2, 20264 PRIMARY DOCUMENT
- Oct 2, 20264 PRIMARY DOCUMENT
- Sep 18, 20268-K
- Sep 8, 2026DEFA14A DEFINITIVE 14A ADDITIONAL MATERIALS
- Aug 20, 20268-K
- Aug 7, 2026DEFA14A DEFINITIVE 14A ADDITIONAL MATERIALS
- Aug 7, 202610-Q QUARTERLY REPORT
- Aug 5, 2026DEF 14A DEFINITIVE 14A
- Jul 23, 2026ARS ANNUAL REPORT TO SECURITY HOLDERS
- Jul 13, 2026PRE 14A PRELIMINARY 14A
- Jul 2, 20264 PRIMARY DOCUMENT
- Jul 2, 20264 PRIMARY DOCUMENT
- Jul 2, 20264 PRIMARY DOCUMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8